Unless patients with metastatic colorectal cancer (mCRC) are microsatellite instability high, they generally receive a first and second line regimen of treatment with fluorouracil-based chemotherapy (in combination with oxaliplatin and/or irinotecan), anti-vascular endothelial growth factor (anti-VEGF)-based therapy (mainly bevacizumab [BEV]), and anti-epidermal growth factor receptor (anti-EGFR)-targeted therapies (e.g., in patients with RAS and BRAF wild-type tumors in left colon, or specifically, anti-EGFR with encorafenib for patients with BRAF V600E mutated tumors) [1, 2]. This evidence concerns the gene BRAF and metastatic colorectal cancer.